The Transcription Factor Mrr1p Controls Expression of the MDR1 Efflux Pump and Mediates Multidrug Resistance in Candida albicans
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Constitutive overexpression of the MDR1 (multidrug resistance) gene, which encodes a multidrug efflux pump of the major facilitator superfamily, is a frequent cause of resistance to fluconazole and other toxic compounds in clinical Candida albicans strains, but the mechanism of MDR1 upregulation has not been resolved. By genome-wide gene expression analysis we have identified a zinc cluster transcription factor, designated as MRR1 (multidrug resistance regulator), that was coordinately upregulated with MDR1 in drug-resistant, clinical C. albicans isolates. Inactivation of MRR1 in two such drug-resistant isolates abolished both MDR1 expression and multidrug resistance. Sequence analysis of the MRR1 alleles of two matched drug-sensitive and drug-resistant C. albicans isolate pairs showed that the resistant isolates had become homozygous for MRR1 alleles that contained single nucleotide substitutions, resulting in a P683S exchange in one isolate and a G997V substitution in the other isolate. Introduction of these mutated alleles into a drug-susceptible C. albicans strain resulted in constitutive MDR1 overexpression and multidrug resistance. By comparing the transcriptional profiles of drug-resistant C. albicans isolates and mrr1Delta mutants derived from them and of C. albicans strains carrying wild-type and mutated MRR1 alleles, we defined the target genes that are controlled by Mrr1p. Many of the Mrr1p target genes encode oxidoreductases, whose upregulation in fluconazole-resistant isolates may help to prevent cell damage resulting from the generation of toxic molecules in the presence of fluconazole and thereby contribute to drug resistance. The identification of MRR1 as the central regulator of the MDR1 efflux pump and the elucidation of the mutations that have occurred in fluconazole-resistant, clinical C. albicans isolates and result in constitutive activity of this trancription factor provide detailed insights into the molecular basis of multidrug resistance in this important human fungal pathogen.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Construction of mrr1Δ Mutants and Complemented Strains (A) Structure of the deletion cassette from plasmid pZCF36M2 (top), which was used to delete the MRR1 ORF in strains SC5314, F5, G5, and CAG48B, and genomic structure of the MRR1 locus in the parental strains (bottom). The MRR1 coding region is represented by the white arrow and the upstream and downstream regions (5′MRR1 and 3′MRR1) by the solid lines. The SAT1 flipper cassette (SAT1-FLIP), in which the caFLP gene is expressed from the inducible SAP2 promoter [30], is represented by the grey rectangle bordered by FRT sites (black arrows). The 34 bp FRT sites are not drawn to scale. The probes used for Southern hybridization analysis of the mutants are indicated by the black bars. (B) Structure of the DNA fragments from plasmids pZCF36K2, pZCF36K3, pZCF36K4, and pZCF36K5 (top), which were used for integration the MRR1 F2–1, MRR1 F5, MRR1 G2–2, and MRR1 G5 alleles, respectively, into the disrupted mrr1 locus of homozygous and heterozygous mrr1Δ mutants (bottom) using the caSAT1 selection marker (grey arrow). TACT1, transcription termination sequence of the ACT1 gene. Only relevant restriction sites are given in (A) and (B): A, ApaI; B, BglII; E, EcoRI; N, NsiI; Nd, NdeI; P, PstI; S, SalI; ScI, SacI; ScII, SacII; X, XhoI. The PstI and NsiI sites shown in parenthesis were destroyed by the cloning procedure. (C) Southern hybridization of NsiI-digested genomic DNA of mrr1Δ mutants derived from strain SC5314 and of strains with reinserted MRR1 alleles with the MRR1-specific probe 1. The sizes of the hybridizing fragments (in kb) are given on the left side of the blot and their identities are indicated on the right. The genotype of the strains is given above the respective lanes. Only one of the two independently constructed series of strains is shown. Inactivation of MRR1 in the clinical isolates F5 and G5 and the reporter strain CAG48B and reinsertion of different MRR1 alleles in mrr1 mutants of the reporter strain occurred in an analogous fashion.](https://figures.cochat.ai/paper-figures/92ad36a1a1ee4d74832061200ec93001/the-transcription-factor-mrr1p-controls-expression-of-the-mdr1-efflux-pump-and-figure-2.jpg)




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mutual dependence of Mrr1 and Snf2 occupancy at the MDR1 promoter is consistent with their requirements for MDR1 transcriptional activation (17) (Fig. 1).”
From Candida albicans Swi/Snf and Mediator Complexes Differentially Regulate Mrr1-Induced MDR1 Expression and Fluconazole Resistance (2017) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hyperactivation of Mrr1 by xenobiotics and the subsequent expression of MDR1 play a key role in detoxifying compounds such as benomyl (17, 19–21).”
From Candida albicans Swi/Snf and Mediator Complexes Differentially Regulate Mrr1-Induced MDR1 Expression and Fluconazole Resistance (2017) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Interestingly, deletion of MRR1 in each MDR1-overexpressing isolate did not yield identical MICs to strains lacking MDR1 in the same background.”
From Molecular and genetic basis of azole antifungal resistance in the opportunistic pathogenic fungus Candida albicans (2020) · cites this paper as [103]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Expression of MDR1 is the major, but not the exclusive, fluconazole resistance pathway in strains with MRR1GOF mutations (17, 19).”
From Candida albicans Swi/Snf and Mediator Complexes Differentially Regulate Mrr1-Induced MDR1 Expression and Fluconazole Resistance (2017) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“MRR1GOF mutations induce drug efflux gene expression and are commonly found in fluconazole-resistant C. albicans clinical isolates (1, 2, 17, 18).”
From Candida albicans Swi/Snf and Mediator Complexes Differentially Regulate Mrr1-Induced MDR1 Expression and Fluconazole Resistance (2017) · cites this paper as [17]
Experimental — accuracy not yet measured
18 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance
White, T. C., Marr, K. A., & Bowden, R. A. (1998) · Clinical Microbiology Reviews · doi:10.1128/cmr.11.2.382 · Cited by 1,353 · cited 1×
“candidiasis, which frequently affects HIV-infected persons and AIDS patients [2].”
BackgroundA rapid and simple method for preparation of RNA from Saccharomyces cerevisiae
Schmitt, M. E., Brown, T. A., & Trumpower, B. L. (1990) · Nucleic Acids Research · doi:10.1093/nar/18.10.3091 · Cited by 1,338 · cited 1×
“Total RNA was isolated using the hot SDS-phenol method [52].”
MethodSanglard, D., Kuchler, K., Ischer, F., Pagani, J. L., Monod, M., & Bille, J. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.11.2378 · Cited by 815 · cited 1×
“years ago [3], many studies have shown that the major mechanism of resistance to the widely used antifungal agent fluconazole in clinical C.”
BackgroundThe SAT1 flipper, an optimized tool for gene disruption in Candida albicans
Reuß, O., Vik, Å., Kolter, R., & Morschhäuser, J. (2004) · Gene · doi:10.1016/j.gene.2004.06.021 · Cited by 742
Self-citationWhite, T. C. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.7.1482 · Cited by 612 · cited 2×
“isolates from the same patient, so-called matched isolates, have proved an excellent tool to study the molecular basis of drug resistance [3–10].”
MethodSanglard, D., Ischer, F., Monod, M., & Bille, J. (1997) · Microbiology · doi:10.1099/00221287-143-2-405 · Cited by 587
Prasad, R., De Wergifosse, P., Goffeau, A., & Balzi, E. (1995) · Current Genetics · doi:10.1007/bf00352101 · Cited by 486
Perea, S., López-Ribot, J. L., Kirkpatrick, W. R., McAtee, R. K., Santillán, R. A., Martı́nez, M., Calabrese, D., Sanglard, D., & Patterson, T. F. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2676-2684.2001 · Cited by 470 · cited 2×
“isolates from the same patient, so-called matched isolates, have proved an excellent tool to study the molecular basis of drug resistance [3–10].”
MethodSanglard, D., Ischer, F., Koymans, L., & Bille, J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.2.241 · Cited by 465 · cited 1×
“isolates from the same patient, so-called matched isolates, have proved an excellent tool to study the molecular basis of drug resistance [3–10].”
MethodCoste, A. T., Karababa, M., Ischer, F., Bille, J., & Sanglard, D. (2004) · Eukaryotic Cell · doi:10.1128/ec.3.6.1639-1652.2004 · Cited by 407 · cited 8×
“Two main factors, namely 1) the discovery of a cis-regulatory element in the promoters of CDR1 and CDR2 with features that are typical of binding sites of zinc cluster transcription factors, and 2) the observation that homozygosity at the mating type locus was linked with the development of azole resistance in certain…”
BackgroundInfluential
Research works printed but not linked: 1
- OddsFC 1988 Candida and candidosis: a review and bibliography London Bailliere Tindall
Cited by
Items 101–200 of 359
Chew, S. Y., & Than, L. T. L. (2016) · Mycoses · doi:10.1111/myc.12455 · Cited by 63
Evolution of drug resistance in an antifungal-naive chronic Candida lusitaniae infection
Demers, E. G., Biermann, A. R., Masonjones, S., Crocker, A. W., Ashare, A., Stajich, J. E., & Hogan, D. A. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1807698115 · Cited by 67
“albicans, Mdr1 contributes to the elevated FLZ MIC in strains with constitutively active Mrr1 variants (22, 29, 30).”
BackgroundZhang, L., Xiao, M., Watts, M. R., Wang, H., Fan, X., Kong, F., & Xu, Y.-C. (2015) · BMC Infectious Diseases · doi:10.1186/s12879-015-1086-6 · Cited by 62
“The previous studies have demonstrated that a gainof-function mutation in one MRR1 allele results only in slightly decreased susceptibilities to the azoles and the loss of heterozygosity further increases drug resistance [15, 16].”
BackgroundSasse, C., Schillig, R., Dierolf, F., Weyler, M., Schneider, S., Mogavero, S., Rogers, P. D., & Morschhäuser, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025623 · Cited by 61
Self-citationEpp, E., Vanier, G., Harcus, D., Lee, A. Y., Jansen, G., Hallett, M., Sheppard, D. C., Thomas, D. Y., Munro, C. A., Mullick, A., et al. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000753 · Cited by 61
“albicans [35,52,53].”
Genetic basis of antifungal drug resistance
Marie, C., & White, T. C. (2009) · Current Fungal Infection Reports · doi:10.1007/s12281-009-0021-y · Cited by 57
Multidrug transporters of Candida species in clinical azole resistance
Prasad, R., Nair, R., & Banerjee, A. (2019) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2019.103252 · Cited by 57
Nuclear receptor-like transcription factors in fungi
Näär, A. M., & Thakur, J. K. (2009) · Genes & Development · doi:10.1101/gad.1743009 · Cited by 61
“In C. albicans, the Tac1p and Mrr1p zinc cluster transcription factors activate CaCDR1/CaCDR2 and CaMDR1, respectively, and mediate responses to xenobiotics, such as azoles and rifampicin (Coste et al. 2004; Morschhauser et al. 2007).”
BackgroundVu, B. G., Thomas, G. H., & Moye-Rowley, W. S. (2019) · mBio · doi:10.1128/mbio.00934-19 · Cited by 59
“albicans, an important azole resistance mechanism is provided by substitution mutations with the Erg11 enzyme, the target of azole drugs (reviewed in reference 23), as well as GOF mutations in transcriptional regulators like Tac1 (24) and Mrr1 (25).”
BackgroundDeciphering the Mrr1/Mdr1 Pathway in Azole Resistance of Candida auris
Li, J., Coste, A. T., Bachmann, D., Sanglard, D., & Lamoth, F. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00067-22 · Cited by 59
“TheMRR1N647T mutation reduces azole susceptibility via Mdr1 and not Cdr1.”
BackgroundInfluentialShahi, P., & Moye-Rowley, W. S. (2009) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2008.12.012 · Cited by 57
“CaMrr1 was demonstrated to be required for overproduction of Ca MDR1 mRNA in azole resistant strains [58].”
Salazar, S. B., Simões, R., Pedro, N. A., Pinheiro, M. J. F., Carvalho, M. F. N. N., & Mira, N. P. (2020) · Journal of Fungi · doi:10.3390/jof6010023 · Cited by 63
“An important feature of these “hyper-active” alleles is that they become active even when azoles are absent [78,85,88].”
BackgroundIbuprofen reverts antifungal resistance on Candida albicans showing overexpression of CDR genes
Ricardo, E., Costa-de-Oliveira, S., Silva Dias, A., Guerra, J., Rodrigues, A. G., & Pina-Vaz, C. (2009) · FEMS Yeast Research · doi:10.1111/j.1567-1364.2009.00504.x · Cited by 56
Competitive Fitness of Fluconazole-Resistant Clinical Candida albicans Strains
Popp, C., Hampe, I. A. I., Hertlein, T., Ohlsen, K., Rogers, P. D., & Morschhäuser, J. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00584-17 · Cited by 56
“Earlier work has shown that the MDR1-overexpressing isolate F5, which contains an MRR1 GOF mutation (9), also overexpresses ERG11 (22).”
BackgroundSelf-citationMernke, D., Dahm, S., Walker, A., Lalève, A., Fillinger, S., Leroch, M., & Hahn, M. (2011) · Phytopathology · doi:10.1094/phyto-02-11-0046 · Cited by 57
Mayr, E.-M., Ramírez-Zavala, B., Krüger, I., & Morschhäuser, J. (2020) · mSphere · doi:10.1128/msphere.00279-20 · Cited by 55
Self-citationEldesouky, H. E., Salama, E. A., Li, X., Hazbun, T. R., Mayhoub, A. S., & Seleem, M. N. (2020) · Scientific Reports · doi:10.1038/s41598-020-64571-7 · Cited by 55
Azole resistance in Candida auris: mechanisms and combinatorial therapy
Jangir, P., Kalra, S., Tanwar, S., & Bari, V. K. (2023) · Apmis · doi:10.1111/apm.13336 · Cited by 61
Al-Mulla, Z., & Christensen, R. D. (1995) · Clinics in Perinatology · doi:10.1016/s0095-5108(18)30277-x · Cited by 57
Xie, F., Chang, W., Zhang, M., Li, Y., Li, W., Shi, H., Zheng, S., & Lou, H. (2016) · Scientific Reports · doi:10.1038/srep33687 · Cited by 55
Pais, P., Galocha, M., Viana, R., Cavalheiro, M., Pereira, D., & Teixeira, M. C. (2019) · Microbial Cell · doi:10.15698/mic2019.03.670 · Cited by 51
Morio, F., Pagniez, F., Besse, M., Gay‐Andrieu, F., Miegeville, M., & Pape, P. L. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.07.013 · Cited by 59
Nishimoto, A. T., Wiederhold, N. P., Flowers, S. A., Zhang, Q., Kelly, S. L., Morschhäuser, J., Yates, C. M., Hoekstra, W. J., Schotzinger, R. J., Garvey, E. P., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00341-19 · Cited by 52
Self-citationPerlin, D. S., & Wiederhold, N. P. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix121 · Cited by 49
Liu, Z., & Myers, L. C. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01344-17 · Cited by 51
“C-terminal tagging of SNF2 and MED17 in SC5314 and SCMRR1M4A (mrr1Δ/Δ) (17) was performed using the previously described methods and constructs (36).”
BackgroundMethodInfluentialVandeputte, P., Pradervand, S., Ischer, F., Coste, A. T., Ferrari, S., Harshman, K., & Sanglard, D. (2012) · Eukaryotic Cell · doi:10.1128/ec.00134-12 · Cited by 51
“Mutations in these factors result in an 88 enhanced transcriptional activation of target genes and this was demonstrated for Tac1 (14, 15), 89 Mrr1 (43), and Upc2 (20, 56).”
BackgroundMilbemycins: More than Efflux Inhibitors for Fungal Pathogens
Silva, L. V., Sanguinetti, M., Vandeputte, P., Torelli, R., Rochat, B., & Sanglard, D. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02040-12 · Cited by 49
“The upregulation of MRR1 is accompanied by upregulation of some of its target genes (35 out of 84 target genes), among which MDR1, a multidrug transporter of the major facilitator family (49).”
BackgroundMogavero, S., Tavanti, A., Senesi, S., Rogers, P. D., & Morschhäuser, J. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01467-10 · Cited by 49
“ment from pMPG2S (14) was used to integrate a PMDR1-GFP reporter fusion at the ACT1 locus of strains MRcan42 and MRcan43, resulting in strains”
BackgroundMethodInfluentialSelf-citationRocha, M. F. G., Bandeira, S. P., de Alencar, L. P., Melo, L. M., Sales, J. A., Paiva, M. D. A. N., Teixeira, C. E. C., Castelo‐Branco, D. D. S. C. M., Pereira‐Neto, W. D. A., Cordeiro, R. D. A., et al. (2017) · Mycoses · doi:10.1111/myc.12611 · Cited by 51
Hampe, I. A. I., Friedman, J., Edgerton, M., & Morschhäuser, J. (2017) · PLoS Pathogens · doi:10.1371/journal.ppat.1006655 · Cited by 52
Self-citationSalari, S., Khosravi, A., Mousavi, S. A. A., & Nikbakht-Brojeni, G. H. (2015) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2015.10.007 · Cited by 50
Hirakawa, M. P., Chyou, D. E., Huang, D., Slan, A. R., & Bennett, R. J. (2017) · Genetics · doi:10.1534/genetics.117.300295 · Cited by 47
“…CDR2 that are involved with drug efflux out of the cell (Prasad et al. 1995; Sanglard et al. 1997), as well as the transcription factor MRR1 that regulates MDR1, a gene on Chr6 that encodes another multidrug efflux pump involved in FL resistance (Wirsching et al. 2000; Morschhauser et al. 2007).”
BackgroundLi, X., Robbins, N., O'Meara, T. R., & Cowen, L. E. (2017) · Molecular Microbiology · doi:10.1111/mmi.13578 · Cited by 43
“We assessed fluconazole susceptibility of two different matched sets of clinical isolates (isolates F and isolates G) that had acquired fluconazole resistance due to overexpression of MDR1.”
BackgroundInfluentialInhibitory activity of hinokitiol against biofilm formation in fluconazole-resistant Candida species
Kim, D. J., Lee, M. W., Choi, J. S., Lee, S. G., Park, J. Y., & Kim, S. W. (2017) · PLoS ONE · doi:10.1371/journal.pone.0171244 · Cited by 50
Candida albicans: An Emerging Yeast Model to Study Eukaryotic Genome Plasticity
Legrand, M., Jaitly, P., Feri, A., d’Enfert, C., & Sanyal, K. (2019) · Trends in Genetics · doi:10.1016/j.tig.2019.01.005 · Cited by 52
Willers, C., Wentzel, J. F., Plessis, D., Gouws, C., & Hamman, J. H. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1265105 · Cited by 51
Popp, C., Ramírez-Zavala, B., Schwanfelder, S., Krüger, I., & Morschhäuser, J. (2019) · mBio · doi:10.1128/mbio.02740-18 · Cited by 42
Self-citationWu, M., Xu, X., Hu, R. M., Chen, Q., Chen, L., Yuan, Y., Li, J., Zhou, L., Feng, S., Wang, L., et al. (2023) · Advanced Science · doi:10.1002/advs.202207736 · Cited by 50
Host-Pathogen Interactions Mediated by MDR Transporters in Fungi: As Pleiotropic as it Gets!
Cavalheiro, M., Pais, P., Galocha, M., & Teixeira, M. C. (2018) · Genes · doi:10.3390/genes9070332 · Cited by 47
“ABC transporters in particular have been first described as targets of CaTac1 and CgPdr1 [26,48,76–78], but several MFS transporters are also activated by CaMrr1 and CgPdr1 [65,66,71,72], thus reinforcing the role of multiple transporters in azole resistance pathways.”
BackgroundInfluentialEmerging Mechanisms of Drug Resistance in Candida albicans
Prasad, R., Nair, R., & Banerjee, A. (2019) · Progress in molecular and subcellular biology · doi:10.1007/978-3-030-13035-0_6 · Cited by 45
Papp, C., Bohner, F., Kocsis, K., Varga, M., Szekeres, A., Bodai, L., Willis, J. R., Gabaldón, T., Tóth, R., Nosanchuk, J. D., et al. (2020) · mSphere · doi:10.1128/msphere.00821-20 · Cited by 42
“According to the sequencing results, the resistance in our FLUEVO and VOREVO strains possibly developed due to two different SNPs in the MRR1 gene, responsible for MDR1 transcription activation (21).”
ResultCoste, A. T., Ramsdale, M., Ischer, F., & Sanglard, D. (2008) · Microbiology · doi:10.1099/mic.0.2007/016063-0 · Cited by 41
“Very recently, the transcription factor MRR1, which also possesses a Zn(2)-Cys(6) DNA-binding motif, was discovered as a major regulator of MDR1 (Morschhauser et al., 2007).”
BackgroundThe cellular and molecular defense mechanisms of the Candida yeasts against azole antifungal drugs
Noël, T. (2012) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2012.04.004 · Cited by 47
Rocha, M. F. G., de Alencar, L. P., Paiva, M. A. N., Melo, L. M., Bandeira, S. P., de Ponte, Y. B., Sales, J. A., Guedes, G. M. D. M., Castelo‐Branco, D. D. S. C. M., Bandeira, T. J. P. G., et al. (2016) · Mycoses · doi:10.1111/myc.12457 · Cited by 43
Eddouzi, J., Lohberger, A., Vogne, C., Manaï, M., & Sanglard, D. (2013) · Medical Mycology · doi:10.3109/13693786.2013.800239 · Cited by 48
Stevenson, E. M., Gaze, W. H., Gow, N. A. R., Hart, A. J., Schmidt, W., Usher, J., Warris, A., Wilkinson, H., & Murray, A. K. (2022) · Frontiers in Fungal Biology · doi:10.3389/ffunb.2022.918717 · Cited by 42
“Comparatively less is known about the fitness costs of AFR in fungi, though there is evidence that, as with ABR, further evolution may ameliorate incurred fitness costs via compensatory mutations (Cowen et al., 2002; Barker et al., 2004; Anderson, 2005; Morschhäuser et al., 2007; Hof, 2008; Sharma et al., 2015; Morsch…”
BackgroundVasicek, E. M., Berkow, E. L., Bruno, V. M., Mitchell, A. P., Wiederhold, N. P., Barker, K. S., & Rogers, P. D. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00064-14 · Cited by 36
“resulting in upregulation of MDR1, CDR1 and CDR2, and ERG11 respectively, and decreased 280 fluconazole susceptibility (41, 42, 45-47).”
BackgroundSelf-citationSchubert, S., Popp, C., Rogers, P. D., & Morschhäuser, J. (2011) · Eukaryotic Cell · doi:10.1128/ec.05100-11 · Cited by 39
“the mrr1 mutants SCMRR1M4A and SCMRR1M4B (22), and strain”
BackgroundMethodSelf-citationVu, B. G., Stamnes, M. A., Li, Y., Rogers, P. D., & Moye-Rowley, W. S. (2021) · PLOS Genetics · doi:10.1371/journal.pgen.1009582 · Cited by 39
Self-citationThe Impact of Gene Dosage and Heterozygosity on the Diploid Pathobiont Candida albicans
Liang, S.-H., & Bennett, R. J. (2019) · Journal of Fungi · doi:10.3390/jof6010010 · Cited by 43
Efficient and rapid identification of Candida albicans allelic status using SNP-RFLP
Forche, A., Steinbach, M., & Berman, J. (2009) · FEMS Yeast Research · doi:10.1111/j.1567-1364.2009.00542.x · Cited by 35
“Increased resistance to antifungal drugs can also arise by point mutations in ERG11 (White, 1997), TAC1 (Coste et al., 2004; Coste et al., 2006), or MRR1 (a transcriptional activator of MDR1, a major facilitator efflux pump) (Morschhauser et al., 2007; Dunkel et al., 2008).”
BackgroundCandida parapsilosis Mdr1B and Cdr1B Are Drivers of Mrr1-Mediated Clinical Fluconazole Resistance
Doorley, L. A., Rybak, J. M., Berkow, E. L., Zhang, Q. H., Morschhäuser, J., & Rogers, P. D. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00289-22 · Cited by 40
“In C. albicans, activation of Mrr1 leads to upregulation of a distinct repertoire of genes, including the gene encoding the transporter Mdr1 (17, 25).”
BackgroundInfluentialSelf-citationLi, Y., Chang, W., Zhang, M., Li, X., Jiao, Y., & Lou, H. (2015) · FEMS Yeast Research · doi:10.1093/femsyr/fov001 · Cited by 36
“…(ABC) transporter genes CDR1 and CDR2, the major facilitator superfamily pumps (MDR1 and FLU1) (Calabrese, Bille and Sanglard 2000; Morschhäuser et al., 2007; Holmes et al., 2008), the pointmutations or alterations of a cytochrome P450 (encoded by CYP51) involved in the 14-…”
BackgroundGene Deletion in Candida albicans Wild-Type Strains Using the SAT1-Flipping Strategy
Sasse, C., & Morschhäuser, J. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-539-8_1 · Cited by 35
Self-citationRepurposing an inhibitor of ribosomal biogenesis with broad anti-fungal activity
Sun, N., Li, D., Zhang, Y., Killeen, K., Groutas, W., & Calderone, R. (2017) · Scientific Reports · doi:10.1038/s41598-017-17147-x · Cited by 36
How urgent is the need for new antifungals?
Stewart, A. G., & Paterson, D. L. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1935868 · Cited by 36
Li, Z., Huang, Y., Tu, J., Yang, W., Liu, N., Wang, W., & Sheng, C. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00165 · Cited by 36
Pais, P., Costa, C., Cavalheiro, M., Romão, D., & Teixeira, M. C. (2016) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2016.00131 · Cited by 37
Targeting Candida spp. to develop antifungal agents
Salci, T. P., Negri, M., Abadio, A. K. R., Svidzinski, T. I. E., & Kioshima, É. S. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.01.003 · Cited by 39
Rep1p negatively regulating MDR1 efflux pump involved in drug resistance in Candida albicans
Chen, C.-G., Yang, Y.-L., Tseng, K., Shih, H., Liou, C., Lin, C.-C., & Lo, H. (2009) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2009.06.003 · Cited by 35
Eldesouky, H. E., Salama, E. A., Hazbun, T. R., Mayhoub, A. S., & Seleem, M. N. (2020) · Scientific Reports · doi:10.1038/s41598-020-62976-y · Cited by 33
Antimicrobial peptide MUC7 12-mer activates the calcium/calcineurin pathway in Candida albicans
Lis, M., Liu, T. T., Barker, K. S., Rogers, P. D., & Bobek, L. A. (2010) · FEMS Yeast Research · doi:10.1111/j.1567-1364.2010.00638.x · Cited by 34
“Labelling and hybridizations were performed as per the manufacturer’s protocol and Morschhauser et al. (2007).”
Self-citationResistance to antifungal therapies
Prasad, R., Banerjee, A., & Shah, A. H. (2017) · Essays in Biochemistry · doi:10.1042/ebc20160067 · Cited by 37
Beyond Conventional Antifungals: Combating Resistance Through Novel Therapeutic Pathways
Hetta, H. F., Melhem, T., Aljohani, H. M., Salama, A., Ahmed, R., Elfadil, H., Alanazi, F. E., Ramadan, Y. N., Battah, B., Rottura, M., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18030364 · Cited by 35
DNA microarray analysis of fluconazole resistance in a laboratory Candida albicans strain
Yan, L., Zhang, J., Li, M., Cao, Y., Xu, Z., Cao, Y., Gao, P., Wang, Y., & Jiang, Y. (2008) · Acta Biochimica et Biophysica Sinica · doi:10.1111/j.1745-7270.2008.00483.x · Cited by 30
Manoharlal, R., Gorantala, J., Sharma, M., Sanglard, D., & Prasad, R. (2010) · Microbiology · doi:10.1099/mic.0.035154-0 · Cited by 31
The role of gene copy number variation in antimicrobial resistance in human fungal pathogens
Jay, A., Jordan, D., Gerstein, A. C., & Landry, C. R. (2025) · npj Antimicrobials and Resistance · doi:10.1038/s44259-024-00072-1 · Cited by 30
Multidrug-Resistant Transporter Mdr1p-Mediated Uptake of a Novel Antifungal Compound
Sun, N., Li, D., Fonzi, W., Li, X., Zhang, L., & Calderone, R. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01504-13 · Cited by 30
“3A and B), consistent with previous findings that MDR1 overexpression due to MRR1 gain of expression contributes to fluconazole resistance in CaMDR (14, 18).”
BackgroundInfluentialLuna-Tapia, A., Willems, H. M. E., Parker, J. E., Tournu, H., Barker, K. S., Nishimoto, A. T., Rogers, P. D., Kelly, S. L., Peters, B. M., & Palmer, G. E. (2018) · mBio · doi:10.1128/mbio.00225-18 · Cited by 29
Self-citationJúnior, L. R. B., Gast, C. E., Mao, Y., & Wong, B. (2010) · Eukaryotic Cell · doi:10.1128/ec.00355-09 · Cited by 36
“cerevisiae and also that fluconazole MICs increased when CDR1, CDR2 (36, 53), and MDR1 (31) were overexpressed in C.”
BackgroundAntifungal resistance: Emerging mechanisms and implications (Review)
Kadariswantiningsih, I. N., Empitu, M. A., Santosa, T., & Alimu, Y. (2025) · Molecular Medicine Reports · doi:10.3892/mmr.2025.13612 · Cited by 30
“…upregulation of the efflux pump, increasing the expulsion of azole antifungals such as fluconazole from the cell, thereby conferring resistance (52,53). clinical isolates of C. albicans with duplicated MDR1 genes exhibit high levels of resistance to fluconazole, the most commonly used antifungal…”
Alex, D., Gay‐Andrieu, F., May, J. P., Thampi, L. M., Dou, D., Mooney, A., Groutas, W. C., & Calderone, R. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00477-12 · Cited by 28
“Strains were selected to represent some of the mechanisms that are commonly found in clinically resistant isolates (10, 16, 17, 19, 22, 34, 38, 39, 46, 56, 59) (Tables 4 and 5).”
BackgroundResearch of Mrr1, Cap1 and MDR1 in Candida albicans resistant to azole medications
Feng, W., Yang, J., Yang, L., Li, Q., Zhu, X., Xi, Z., Qiao, Z., & Wen, C. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.5518 · Cited by 31
“Mrr1, a zinc cluster transcription factor, is not only indispensable for the constitutive overexpression of MDR1, but also for chemical-induced expression (21).”
Mechanisms of Antifungal Drug Resistance in Candida Dubliniensis
Coleman, D. C., Moran, G. P., McManus, B. A., & Sullivan, D. J. (2010) · Future Microbiology · doi:10.2217/fmb.10.51 · Cited by 30
Networks of genes modulating the pleiotropic drug response in Saccharomyces cerevisiae
Yibmantasiri, P., Bircham, P. W., Maass, D. R., Bellows, D. S., & Atkinson, P. H. (2013) · Molecular BioSystems · doi:10.1039/c3mb70351g · Cited by 27
Ramírez-Zavala, B., Mogavero, S., Schöller, E., Sasse, C., Rogers, P. D., & Morschhäuser, J. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03065-14 · Cited by 25
“In all cases investigated so far, MDR1 overexpression is caused by gain-of-function mutations in Mrr1 that render the transcription factor constitutively active (9, 13, 14).”
BackgroundSelf-citationGlutathione Metabolism in Candida albicans Resistant Strains to Fluconazole and Micafungin
Maras, B., Angiolella, L., Mignogna, G., Vavala, E., Macone, A., Colone, M., Pitari, G., Stringaro, A., Duprè, S., & Palamara, A. T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098387 · Cited by 28
“Molecular analyses showed that CO23RFLC had acquired a marked increased expression of the MDR1 gene encoding for an efflux pump protein mainly responsible for the drug-resistance, due to a mutation in the transcription factor gene MRR1 [16] whereas CO23RFK had a homozygous mutation (S645Y substitution) in the FSK1 gen…”
BackgroundDoorley, L. A., Barker, K. S., Zhang, Q., Rybak, J. M., & Rogers, P. D. (2023) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2023.08.030 · Cited by 24
Self-citationShrivastava, M., Kouyoumdjian, G. S., Kirbizakis, E., Ruiz, D., Henry, M., Vincent, A. T., Sellam, A., & Whiteway, M. S. (2023) · mBio · doi:10.1128/mbio.01807-23 · Cited by 24
Wang, Y., Liu, J., Shi, C., Li, W., Zhao, Y., Yan, L., & Xiang, M.-J. (2015) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2015.08.001 · Cited by 26
Nishimoto, A. T., Zhang, Q., Hazlett, B., Morschhäuser, J., & Rogers, P. D. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00078-19 · Cited by 24
Self-citationDemin, K. A., Refeld, A. G., Bogdanova, A. A., Prazdnova, E. V., Popov, I. V., Kutsevalova, O. Y., Ermakov, A. M., Bren, A. B., Rudoy, D. V., Chistyakov, V. A., et al. (2021) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-021-09776-6 · Cited by 25
Novel Regulatory Mechanisms of Pathogenicity and Virulence to Combat MDR inCandida albicans
Hameed, S., & Fatima, Z. (2013) · International Journal of Microbiology · doi:10.1155/2013/240209 · Cited by 28
“7372 whichwas subsequently known asMRR1 [114].”
Virulence Traits and Azole Resistance in Korean Candida auris Isolates
Byun, S. A., Kwon, Y. J., Lee, G. Y., Choi, M. J., Jeong, S. H., Kim, D., Choi, M. H., Kee, S., Kim, S. H., Shin, M., et al. (2023) · Journal of Fungi · doi:10.3390/jof9100979 · Cited by 26
Zhou, X., Hilk, A. L., Solis, N. V., Scott, N. E., Beach, A., Soisangwan, N., Billings, C. L., Burrack, L. S., Filler, S. G., & Selmecki, A. M. (2024) · Nature Microbiology · doi:10.1038/s41564-024-01795-7 · Cited by 23
Transcription Factor ADS-4 Regulates Adaptive Responses and Resistance to Antifungal Azole Stress
Wang, K., Zhang, Z., Chen, X., Sun, X., Jin, C., Liu, H., & Li, S. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00542-15 · Cited by 25
“albicans increase resistance to azoles (51).”
Xenobiotic Efflux in Bacteria and Fungi: A Genomics Update
Barabote, R. D., Thekkiniath, J., Strauss, R. E., Vediyappan, G., Fralick, J. A., & Francisco, M. J. S. (2011) · Advances in enzymology and related areas of molecular biology/Advances in enzymology and related subjects · doi:10.1002/9780470920541.ch6 · Cited by 26
Induction of Candida albicans Drug Resistance Genes by Hybrid Zinc Cluster Transcription Factors
Schneider, S., & Morschhäuser, J. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04448-14 · Cited by 23
“albicans isolate (8), a C-terminal 3 HA tag, which acts like a gain-of-function mutation (27), or a C-terminal Gal4 activation domain (34).”
BackgroundMethodSelf-citationZou, Z., Zhang, J., Zhang, H., Liu, H., Li, Z., Cheng, D., Chen, J., Liu, L., Ni, M., Zhang, Y. X., et al. (2014) · Journal of drug targeting · doi:10.3109/1061186x.2014.936870 · Cited by 23
“Many factors attribute to cancer MDR [5,6,16].”
BackgroundBergin, S. A., Doorley, L. A., Rybak, J. M., Wolfe, K. H., Butler, G., Cuomo, C. A., & Rogers, P. D. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01619-23 · Cited by 24
“Likewise, MDR1 , which encodes a transporter of the Major Facilitator Superfamily, is overexpressed in some isolates due to activating mutations in MRR1 , encoding another transcriptional regulator (39).”
BackgroundSelf-citationMaheronnaghsh, M., Teimoori, A., Dehghan, P., & Fatahinia, M. (2022) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.24208 · Cited by 23
Genomic Variation-Mediating Fluconazole Resistance in Yeast
Wang, W., Cai, H., Qu, S.-Y., Lin, W., Liang, C., Liu, H., Xie, Z., & Yuan, Y. (2022) · Biomolecules · doi:10.3390/biom12060845 · Cited by 22
“Surprisingly, most fluconazole-resistant isolates exhibit a constitutive upregulation of MDR1 and homozygous MRR1 mutations [28].”
BackgroundParticipation of the ABC Transporter CDR1 in Azole Resistance of Candida lusitaniae
Borgeat, V., Brandalise, D., Grenouillet, F., & Sanglard, D. (2021) · Journal of Fungi · doi:10.3390/jof7090760 · Cited by 24
“The increased expression of these transporters compared to drug-susceptible isolates relies on the transcriptional control of two major regulators, TAC1 and MRR1 [10,11].”
BackgroundInfluentialThe Ins and Outs of Azole Antifungal Drug Resistance: Molecular Mechanisms of Transport
Zavřel, M., Esquivel, B. D., & White, T. C. (2017) · Springer eBooks · doi:10.1007/978-1-4939-0694-9_29 · Cited by 24
Reboutier, D., Piednoël, M., Boisnard, S., Conti, A., Chevalier, V., Florent, M., Gibot‐Leclerc, S., Silva, B. D., Chastin, C., Fallague, K., et al. (2008) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2008.10.019 · Cited by 22
“, 2007), whereas MDR1 overexpression is the consequence of mutations in Mrr1p (Morschhauser et al., 2007).”
BackgroundCandida auris: The Canary in the Mine of Antifungal Drug Resistance
Montoya, M. C., Moye-Rowley, W. S., & Krysan, D. J. (2019) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.9b00239 · Cited by 21
Dunkel, N., & Morschhäuser, J. (2011) · Eukaryotic Cell · doi:10.1128/ec.00281-10 · Cited by 20
Self-citationMutations in TAC1B drive increased CDR1 and MDR1 expression and azole resistance in Candida auris
Barker, K. S., Santana, D. J., Zhang, Q. H., Peters, T. L., Rybak, J. M., Morschhäuser, J., Cuomo, C. A., & Rogers, P. D. (2025) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00300-25 · Cited by 22
“…can also be due to mutations in the genes encoding the transcriptional regulators Tac1, Mrr1, or Upc2, which result in overexpression of genes encoding the ATP-bind ing cassette (ABC) transporter Cdr1, the major facilitator superfamily (MFS) transporter Mdr1, or Erg11, respectively (7–9).”
Self-citationYang, D., Hu, Y. L., Yin, Z. X., Zeng, G., Li, D., Zhang, Y. Q., Xu, Z., Guan, X. M., Weng, L. X., & Wang, L. H. (2019) · PubMed · doi:10.3967/bes2019.027 · Cited by 20
“Since TAC1 is responsible for CDR1 upregulation, MRR1 is required for the constitutive activation of the MDR1 promoter in azole-resistant strains [39,40] .”
BackgroundHamdy, R., Soliman, S. S. M., Alsaadi, A. I., Fayed, B. E., Hamoda, A. M., Elseginy, S. A., Husseiny, M. I., & Ibrahim, A. S. (2020) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2020.105327 · Cited by 21
“The amount of gene expression was normalized to 18S rRNA (Morschhäuser et al., 2007) and then quantified using the 2(−ΔΔCT) method (Livak and Schmittgen, 2001).”
Method
Metadata
- Authors
- Morschhäuser, J., Barker, K. S., Liu, T. T., Blaß-Warmuth, J., Homayouni, R., & Rogers, P. D.
- Affiliations
- University of Würzburg (DE)
- University of Tennessee Health Science Center (US)
- University of Memphis (US)
- Corresponding author
- Morschhäuser, Joachim
- Venue
- PLoS Pathogens
- Publisher
- Public Library of Science (PLoS)
- Published
- 2007-11-02
- Volume
- 3
- Issue
- 11
- Pages
- e164
- ISSN
- 1553-7366 (ISSN-L)
- 1553-7374
- PMC
- PMC2048531
- OpenAlex
- W2008837893
- Cited by
- 355
- References
- 51
- Citations by year
- 2026: 16 · 2025: 22 · 2024: 17 · 2023: 22 · 2022: 18 · 2021: 18 · 2020: 23 · 2019: 32 · 2018: 14 · 2017: 25 · 2016: 14 · 2015: 13 · 2014: 22 · 2013: 15 · 2012: 16
- FWCI
- 10.35
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Pathogens (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Deutsche Forschungsgemeinschaft (SFB 630, MO 846/3)
- National Institutes of Health (AI058145)
- National Institute of Allergy and Infectious Diseases (R01AI058145, AI058145, R21AI058145)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- MRR1, MDR1, multidrug resistance, Candida albicans, fluconazole resistance, transcription factors, efflux pumps, zinc cluster transcription factors, oxidative enzymes, drug resistance mutations, gene expression regulation, antifungal resistance
- MeSH terms
- Antifungal Agents, Base Sequence, Candida albicans, Flow Cytometry, Humans, Molecular Sequence Data, Mutation, Transcription Factors, Blotting, Southern, Fluconazole, Gene Expression, Gene Expression Regulation, Fungal, In Situ Hybridization, Genes, MDR, Reverse Transcriptase Polymerase Chain Reaction, ATP Binding Cassette Transporter, Subfamily B, Member 1, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling, Drug Resistance, Multiple, Fungal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.